<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25279734</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model.</ArticleTitle><Pagination><StartPage>e109391</StartPage><MedlinePgn>e109391</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e109391</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0109391</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a neurotropic virus capable of inducing severe neurological symptoms and death. No direct targeting antivirals are useful in the treatment of severe EV71 infection. Because of low toxicity and good specificity, monoclonal antibodies (MAb) are a potential candidate for the treatment of viral infections. Therefore, we developed an EV71-specific conformational MAb with high in vitro cross-neutralization activity to heterologous EV71 subgenotypes. The in vivo treatment experiment at different days post-infection indicated that a single treatment of MAb CT11F9 within day 3 post-infection fully protected mice from morbidity and mortality (0% PBS vs. 100% at 10 &#xb5;g/g per body weight ***P&lt;0.0001). Immunohistochemical and histological analysis confirmed that CT11F9 significantly prohibited EV71 VP1 expression in various tissues and prevented EV71-induced myonecrosis. Moreover, thrice-treatment at day 4, 5, 6 post-infection was associated with an increased survival rate (18.2% single vs. 50% thrice at 20 &#xb5;g/g per body weight), and the mice recovered from limb paralysis. Competitive ELISA also confirmed that CT11F9-recognized epitopes were immunodominant in humans. In conclusion, MAb CT11F9 is an ideal candidate to be humanized and used in severe EV71 infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhiqun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Longfa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Delei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Lisheng</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Che</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yixin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shih</LastName><ForeName>James Wai Kuo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qinjian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ningshao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Life Sciences, Xiamen University, Xiamen Fujian, PR China; National Institute of Diagnostics and Vaccine Development in infectious diseases, School of Public Health, Xiamen University, Xiamen Fujian, PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Competing Interests: </b>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>10</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25279734</ArticleId><ArticleId IdType="pmc">PMC4184856</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0109391</ArticleId><ArticleId IdType="pii">PONE-D-14-02300</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chan LG, Parashar UD, Lye MS, Ong FG, Zaki SR, et al. (2000) Deaths of children during an outbreak of hand, foot, and mouth disease in sarawak, malaysia: clinical and pathological characteristics of the disease. For the Outbreak Study Group. Clin Infect Dis 31: 678&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">11017815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, et al. (1999) An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 341: 929&#x2013;935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KP, Goh KT, Chong CY, Teo ES, Lau G, et al. (2003) Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 9: 78&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2873753</ArticleId><ArticleId IdType="pubmed">12533285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F, Ren L, Xiong Z, Li J, Xiao Y, et al. (2009) Enterovirus 71 outbreak in the People's Republic of China in 2008. J Clin Microbiol 47: 2351&#x2013;2352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2708525</ArticleId><ArticleId IdType="pubmed">19439545</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, et al. (2010) Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 10: 778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AC, Carter PJ (2010) Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 10: 301&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pubmed">20414204</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao RY, Han JF, Jiang T, Tian X, Yu M, et al. (2011) In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors. J Clin Virol 51: 246&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim XF, Jia Q, Khong WX, Yan B, Premanand B, et al. (2012) Characterization of an isotype dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS One 7: e29751.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3261156</ArticleId><ArticleId IdType="pubmed">22279543</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GH, Luo YJ, Wu XY, Si BY, Lin L, et al. (2010) Monoclonal antibody induced with inactived EV71-Hn2 virus protects mice against lethal EV71-Hn2 virus infection. Virol J 7: 106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887433</ArticleId><ArticleId IdType="pubmed">20500892</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L, He D, Li Z, Zheng J, Yang L, et al. (2014) Protection against Lethal Enterovirus 71 Challenge in mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop. Theranostics 4: 498&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3964443</ArticleId><ArticleId IdType="pubmed">24669278</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, et al. (2004) A mouse-adapted enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol 78: 7916&#x2013;7924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lum LC, Wong KT, Lam SK, Chua KB, Goh AY, et al. (1998) Fatal enterovirus 71 encephalomyelitis. J Pediatr 133: 795&#x2013;798.</Citation><ArticleIdList><ArticleId IdType="pubmed">9842048</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Li C, He D, Cheng T, Ge S, et al. (2013) Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. Vaccine 31: 425&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">23088887</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, Yan Q, Wang H, Niu J, Li L, et al. (2010) Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS One 5: e11388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2894942</ArticleId><ArticleId IdType="pubmed">20613983</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu F, He D, He S, Wu B, Guan L, et al. (2011) Development of an IgM-capture ELISA for Coxsackievirus A16 infection. J Virol Methods 171: 107&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">20970457</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L, He D, Tang M, Li Z, Liu C, et al. (2014) Development of an enzyme-linked immunosorbent spot assay to measure serum-neutralizing antibodies against coxsackievirus B3. Clin Vaccine Immunol 21: 312&#x2013;320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3957675</ArticleId><ArticleId IdType="pubmed">24391137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu KX, Ng MM, Chu JJ (2010) Developments towards antiviral therapies against enterovirus 71. Drug Discov Today 15: 1041&#x2013;1051.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108380</ArticleId><ArticleId IdType="pubmed">20974282</ArticleId></ArticleIdList></Reference><Reference><Citation>Reading SA, Dimmock NJ (2007) Neutralization of animal virus infectivity by antibody. Arch Virol 152: 1047&#x2013;1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">17516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt AR, Bowen RA, Frederickson S, Maruyama T, Roehrig JT, et al. (2011) Treatment of mice with human monoclonal antibody 24 h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 414: 146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097527</ArticleId><ArticleId IdType="pubmed">21489591</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeraski CA, Siddharthan V, Morrey JD (2011) Treatment of spatial memory impairment in hamsters infected with West Nile virus using a humanized monoclonal antibody MGAWN1. Antiviral Res 91: 43&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3125166</ArticleId><ArticleId IdType="pubmed">21554903</ArticleId></ArticleIdList></Reference><Reference><Citation>He F, Kumar SR, Syed Khader SM, Tan Y, Prabakaran M, et al. (2013) Effective intranasal therapeutics and prophylactics with monoclonal antibody against lethal infection of H7N7 influenza virus. Antiviral Res 100: 207&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954322</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Q, Xia L, Wu WL, Zheng Z, Huo Y, et al. (2011) Properties and therapeutic efficacy of broadly reactive chimeric and humanized H5-specific monoclonal antibodies against H5N1 influenza viruses. Antimicrob Agents Chemother 55: 1349&#x2013;1357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067186</ArticleId><ArticleId IdType="pubmed">21245446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CS, Yao YC, Lin SC, Lee YP, Wang YF, et al. (2007) Retrograde axonal transport: a major transmission route of enterovirus 71 in mice. J Virol 81: 8996&#x2013;9003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1951457</ArticleId><ArticleId IdType="pubmed">17567704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong KC, Badmanathan M, Devi S, Leong KL, Cardosa MJ, et al. (2008) Pathologic characterization of a murine model of human enterovirus 71 encephalomyelitis. J Neuropathol Exp Neurol 67: 532&#x2013;542.</Citation><ArticleIdList><ArticleId IdType="pubmed">18520772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TY, Chang LY, Huang YC, Hsu KH, Chiu CH, et al. (2002) Different proinflammatory reactions in fatal and non-fatal enterovirus 71 infections: implications for early recognition and therapy. Acta Paediatr 91: 632&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">12162592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Yu CK, Wang JR, Su IJ, et al. (2008) Acute chemokine response in the blood and cerebrospinal fluid of children with enterovirus 71-associated brainstem encephalitis. J Infect Dis 198: 1002&#x2013;1006.</Citation><ArticleIdList><ArticleId IdType="pubmed">18710325</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SM, Lei HY, Huang KJ, Wu JM, Wang JR, et al. (2003) Pathogenesis of enterovirus 71 Brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema. J Infect Dis 188: 564&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">12898444</ArticleId></ArticleIdList></Reference><Reference><Citation>Khong WX, Foo DG, Trasti SL, Tan EL, Alonso S (2011) Sustained high levels of interleukin-6 Contribute to the pathogenesis of enterovirus 71 in a neonate mouse model. J Virol 85: 3067&#x2013;3076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067852</ArticleId><ArticleId IdType="pubmed">21228224</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>